Recent Press Releases

QLT Announces Positive Final Results From Phase 1b Retreatment Trial With Oral Synthetic cis-Retinoid (QLT091001) in Subjects With LCA or RP Due to Mutations in RPE65 or LRAT

VANCOUVER, B.C., Sept. 12, 2014 -- QLT Inc. (QLTI) (QLT.TO) ("QLT" or the "Company") today announced positive final results from its international, multi-center, Phase 1b clinical...

Affimed Announces Pricing of Initial Public Offering

HEIDELBERG, Germany, Sept. 12, 2014 -- Affimed Therapeutics today announced the pricing of its initial public offering of 8,000,000 common shares at an initial public offering price of $7.00 per...

Lilly Announces CYRAMZA™ Phase III Second-Line Colorectal Cancer Trial Meets Primary Endpoint of Overall Survival

-- Ramucirumab Plus FOLFIRI Improved Survival in Metastatic Colorectal Cancer following Progression on a Bevacizumab-Based Regimen -- INDIANAPOLIS, Sept. 12, 2014 -- Eli Lilly and Company (NYSE:...

Detailed Results from Biogen Idec and AbbVie's Pivotal Phase 3 Decide Study Further Define the Efficacy and Safety Profile of ZINBRYTA™ (Daclizumab High-Yield Process)

− Data Confirm ZINBRYTA™ is Superior to AVONEX® in Reducing Annualized Relapse Rate – − First Presentation of Full DECIDE Results at ACTRIMS-ECTRIMS Meeting – Today...

Pivotal Therapeutics Inc. Appoints Accomplished Healthcare And Investment Industry Veteran, Prakash Gowd, As Chief Financial Officer

WOODBRIDGE, ON, Sept. 8, 2014 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX:PVTTF; CSE:PVO), ("Pivotal" or the "Company"), a specialty pharmaceutical company with a focus on...

Batu Biologics Names Business Development and R&D Expert as Chief Scientific Officer

International Biotech Market Expert Will Help Boost Company's Business Strategy SAN DIEGO--(BUSINESS WIRE)--Batu Biologics, an immunotherapy company working to develop ValloVax™, the first...

Ignyta Appoints Robert Wild, Ph.D., as Chief Scientific Officer and Senior Vice President, Research

SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (Nasdaq: RXDX), an oncology precision medicine biotechnology company, announced today that Robert Wild, Ph.D., has been appointed as Chief Scientific Officer...

RxTrials Announces Hiring Of Yvonne McCracken As VP Of Clinical Operations And Compliance

ELLICOTT CITY, Md., Sept. 8, 2014 /PRNewswire/ -- RxTrials, a leading international Investigative Site Network (ISN) and consulting firm, has named Yvonne McCracken, MPH to the position of Vice...

CollPlant Names Dr. Nadav Orr Vice President Research And Development

REHOVOT, Israel, September 8, 2014 /PRNewswire/ -- CollPlant (CLPT.TA), a developer and manufacturer of human collagen-based medical products has announced that Dr. Nadav Orr has been appointed Vice...

Aptose Biosciences Recruits Stephen B. Howell, M.D. To Act In The Capacity Of Chief Medical Officer

SAN DIEGO and TORONTO, Sept. 8, 2014 /PRNewswire/ - Aptose Biosciences Inc. (TSX: APS), a clinical-stage company developing new therapeutics and molecular diagnostics that target the underlying...

Bruno Lucidi New CEO In Karolinska Development AB Oncology Companies

STOCKHOLM - September 8, 2014. Karolinska Development announced today that Bruno Lucidi has been appointed Chief Executive Officer of the wholly owned subsidiary KDev Oncology and the portfolio...

Abcam plc (ABC.L) Announces Appointment Of New CEO And Board Changes

• Alan Hirzel succeeds Jonathan Milner as Chief Executive Officer • Jonathan Milner to retain an active role in the company as Deputy Chairman • Peter Keen will not seek re-election to...

Acucela Appoints Biotechnology Industry Veteran and Former Pharmaceutical Executive, Brian O'Callaghan, as Its New President and Chief Operating Officer and Interim CFO; Ryo Kubota, MD, PhD, to Remain in His Role as Chairman and CEO

SEATTLE--(BUSINESS WIRE)--Acucela Inc. (TOKYO:4589), a clinical-stage biotechnology company that specializes in discovering and developing novel therapeutics to treat and slow the progression of...

Scott Peoples Joins Marrone Bio Innovations As Vice President Of Marketing

DAVIS, Calif., Sept. 9, 2014 (GLOBE NEWSWIRE) -- Marrone Bio Innovations, Inc. (MBI), (Nasdaq:MBII), a leading provider of bio-based pest management and plant health products for the agriculture,...

Y-Prime Names Richard Gastineau Chief Operating Officer

MALVERN, Pa., Sept. 9, 2014 /PRNewswire/ -- Y-Prime, Inc., a premier eClinical products and consulting company, today announced the appointment of Richard Gastineau as Chief Operating Officer and...

Second Genome Appoints Karim Dabbagh, Ph.D., As Chief Scientific Officer

SOUTH SAN FRANCISCO, Calif., Sept. 9, 2014 /PRNewswire/ -- Second Genome, Inc., a leader in the development of novel medicines through innovative microbiome science, announced today that it has...

To-BBB technologies BV Taps A New CEO

Anders Harfstrand Joins to-BBB as Chief Executive Officer LEIDEN, Netherlands--(BUSINESS WIRE)--to-BBB, a biopharmaceutical company pioneering treatments for devastating brain diseases, today...

J. Craig Venter Institute Hires Nicole DeBerg As Chief Operating Officer

LA JOLLA, Calif., Sept. 9, 2014 /PRNewswire-USNewswire/ -- The J. Craig Venter Institute (JCVI), a not-for-profit genomic research organization, announced today they have hired Nicole DeBerg as Chief...

Oxygen Biotherapeutics Announces Halt of Oxycyte Phase IIb Traumatic Brain Injury Trial

MORRISVILLE, N.C. -- Oxygen Biotherapeutics, Inc., a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market, today announced...

NovImmune SA Appoints Adrian Mills As Chief Business Officer And Member Of The Executive Committee

Geneva, Switzerland, 10 September 2014 – Novimmune announces today that it has appointed Adrian Mills as the Company's Chief Business Officer and member of the Executive Committee (EC),...